专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4666927A Pharmaceutical compositions of hydroxypyridones 失效
标题翻译：羟基吡啶酮的药物组合物
公开(公告)号：US4666927A
公开(公告)日：1987-05-19
申请号：US651684
申请日：1984-09-18
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4425 , A61K31/4427 , A61P3/00 , A61P7/00 , A61P7/06 , C07D213/63 , C07D213/69 , C07D213/89 , C07D309/40 , C07D401/06 , C07D401/12 , C07F15/02 , C07D239/02
CPC分类号： C07D213/69 , C07D213/89 , C07D309/40 , C07F15/025
摘要： Compounds in which two or more rings, being a 3-hydroxypypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxpyrid-2-one, are linked are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body while the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.

2. 发明授权

US4587240A Pharmaceutical compositions 失效
标题翻译：药物组合物
公开(公告)号：US4587240A
公开(公告)日：1986-05-06
申请号：US651772
申请日：1984-09-18
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： A61K31/44 , A61P3/00 , A61P7/06 , C07D213/89 , C07F15/02 , C07D213/69 , A61K31/555
CPC分类号： C07D213/89 , C07F15/025
摘要： Compounds which are a 1-hydroxypyrid-2-one in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by a substituent selected from aliphatic acyl, aliphatic amide, aliphatic amine, carboxy, cyano, aliphatic ester, halogen, hydroxy and sulpho groups, alkoxy groups and alkoxy groups substituted by an alkoxy, aliphatic amide, aliphatic amine, aliphatic ester, halogen or hydroxy group, aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by substituents selected from aliphatic hydrocarbon groups, halogen groups and aliphatic hydrocarbon groups substituted by a halogen group, or a salt thereof containing a physiolgically acceptable ion or ions, are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body whilst the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.
摘要翻译：其中一个或多个连接到环碳原子上的氢原子被选自脂族酰基，脂族酰胺，脂族胺，羧基，氰基，脂肪族酯，卤素中的取代基取代的1-羟基吡啶-2-酮的化合物，被烷氧基，脂族酰胺，脂族胺，脂族酯，卤素或羟基取代的烷氧基和烷氧基，被烷氧基，脂族酯，卤素或羟基取代的脂族烃基和脂族烃基，但是不包括化合物中氢原子置换的化合物只能由选自脂族烃基，卤素基团和被卤素基团取代的脂族烃基的取代基或其含有生理上可接受的离子或离子的盐所取代，在治疗身体中有毒浓度的金属，特别是铁的患者中，这些化合物在治疗缺铁性贫血方面是有价值的。

3. 发明授权

US4650793A Iron-pyridone complexes for anemia 失效
标题翻译：铁 - 吡啶酮复合物用于贫血
公开(公告)号：US4650793A
公开(公告)日：1987-03-17
申请号：US592543
申请日：1984-03-22
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： C09K3/00 , A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4425 , A61K31/4427 , A61K35/18 , A61P3/00 , A61P7/06 , C07D213/69 , C07D213/89 , C07D309/40 , C07D401/12 , A61K31/555
CPC分类号： C07D213/69 , Y10S514/814
摘要： Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anemia.
摘要翻译：含有与氮原子连接的氢原子被脂肪族酰基或脂肪族烃基取代的3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的铁络合物的药物组合物，被一个取代的脂肪族烃基，或除了可离子化基团以外的多于一个选自脂肪族酰基，烷氧基，脂族胺，脂肪族酰胺，羧基，脂肪族酯，卤素，羟基和磺基的取代基的脂肪族烃基，与环碳原子连接的一个或多个氢原子被所述取代基之一，脂族烃基或被烷氧基，脂族酯，卤素或羟基取代的脂族烃基所取代，但不包括其中所述化合物中的氢原子的取代仅由脂族烃基实现，对于治疗缺铁性贫血是有价值的。

4. 发明授权

US4550101A Iron complexes of hydroxy pyridones useful for treating iron deficiency anemia 失效
标题翻译：用于治疗缺铁性贫血的羟基吡啶酮的铁络合物
公开(公告)号：US4550101A
公开(公告)日：1985-10-29
申请号：US478494
申请日：1983-03-24
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： C07D213/69 , A61K31/555
CPC分类号： C07D213/69
摘要： Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic hydrocarbon group and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are also replaced by an aliphatic hydrocarbon group, are of value for the treatment of iron deficiency anemia.
摘要翻译：含有与氮原子连接的氢原子的3-羟基吡啶-2-酮或3-羟基吡啶-4-酮的铁络合物的药物组合物被脂族烃基代替，并且任选地，其中一个或多个与环碳原子连接的氢原子也被脂族烃基取代，对于治疗缺铁性贫血是有价值的。

5. 再颁专利

USRE36831E Iron-pyridone complexes for anemia 失效
公开(公告)号：USRE36831E
公开(公告)日：2000-08-22
申请号：US390588
申请日：1995-02-17
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： C09K3/00 , A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4425 , A61K31/4427 , A61K35/18 , A61P3/00 , A61P7/06 , C07D213/69 , C07D213/89 , C07D309/40 , C07D401/12 , A61K31/555
CPC分类号： C07D213/69 , Y10S514/814
摘要： Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anemia.

6. 再颁专利

USRE34313E Pharmaceutical compositions 失效
公开(公告)号：USRE34313E
公开(公告)日：1993-07-13
申请号：US769492
申请日：1991-10-01
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： A61K31/44 , C07D213/89 , C07F15/02
CPC分类号： C07D213/89 , A61K31/44 , C07F15/025
摘要： Compounds which are a 1-hydroxypyrid-2-one in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by a substituent selected from aliphatic acyl, aliphatic amide, aliphatic amine, carboxy, cyano, aliphatic ester, halogen, hydroxy and sulpho groups, alkoxy groups and alkoxy groups substituted by an alkoxy, aliphatic amide, aliphatic amine, aliphatic ester, halogen or hydroxy group, aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by substituents selected from aliphatic hydrocarbon groups, halogen groups and aliphatic hydrocarbon groups substituted by a halogen group, or a salt thereof containing a physiolgically acceptable ion or ions, are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body whilst the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.

7. 发明授权

US5104865A Iron complexes of hydroxypyridones useful for treating iron overload 失效
标题翻译：用于处理铁超载的羟基吡啶的铁络合物
公开(公告)号：US5104865A
公开(公告)日：1992-04-14
申请号：US403054
申请日：1989-09-01
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： C07D213/69 , C07D213/89 , C07D309/40 , C07F15/02
CPC分类号： C07D213/69 , C07D213/89 , C07D309/40 , C07F15/025
摘要： Compounds in which two or more rings, being a 3-hydroxpypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxpyrid-2-one, are linked are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body while the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.

8. 发明授权

US4912118A Pharmaceutical compositions 失效
标题翻译：药物组合物
公开(公告)号：US4912118A
公开(公告)日：1990-03-27
申请号：US944872
申请日：1986-12-22
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： C07D213/69 , C07D213/89 , C07D309/40 , C07F15/02
CPC分类号： C07D213/69 , C07D213/89 , C07D309/40 , C07F15/025
摘要： Compounds in which two or more rings, being a 3-hydroxpypyrid-2-one, 3-hydroypyrid-4-one or 1-hydropyrid-2-one, are linked are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body while the iron complexes of such compounds are of value in the treatment of iron deficien
摘要翻译：其中两个或更多个环是3-羟基吡啶-2-酮，3-水吡啶-4-酮或1-氢吡啶-2-酮的化合物在治疗患有毒性浓度为金属，特别是铁，而这些化合物的铁配合物在治疗铁缺乏方面是有价值的

9. 发明授权

US4894455A Pharmaceutically active zinc complexes 失效
标题翻译：药物活性锌配合物
公开(公告)号：US4894455A
公开(公告)日：1990-01-16
申请号：US16083
申请日：1987-02-18
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： A23K1/175 , A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4425 , A61K31/555 , A61P3/00 , C07D213/69 , C07D309/40
CPC分类号： C07D213/69 , A23K20/30 , C07D309/40
摘要： Zinc(II) complexes in which at least one ligand is provided by a compound being:(1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or(2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; are of value in medicine, particularly in the systemic treatment of zinc depletion. Mixtures of these zinc complexes with the metal-free compound(s) providing the ligands contained therein and with iron(III) complexes containing ligands of types (1) and (2) are also of value.

10. 发明授权

US4665064A Pharmaceutical compositions and methods for increasing zinc levels 失效
标题翻译：用于增加锌含量的药物组合物和方法
公开(公告)号：US4665064A
公开(公告)日：1987-05-12
申请号：US666905
申请日：1984-10-31
申请人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
发明人： Robert C. Hider , George Kontoghiorghes , Jack Silver , Michael A. Stockham
IPC分类号： A23K1/175 , A61K31/44 , A61K31/4412 , A61K31/4418 , A61K31/4425 , A61K31/555 , A61P3/00 , C07D213/69 , C07D309/40
CPC分类号： C07D213/69 , A23K20/30 , C07D309/40
摘要： Zinc(II) complexes in which at least one ligand is provided by a compound being:(1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or(2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionizable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; are of value in medicine, particularly in the systemic treatment of zinc depletion. Mixtures of these zinc complexes with the metal-free compound(s) providing the ligands contained therein and with iron(III) complexes containing ligands of types (1) and (2) are also of value.
摘要翻译：锌（II）络合物，其中至少一种配体由以下化合物提供：（1）3-羟基-4-吡喃酮或其中一个或多个与环碳连接的氢原子的3-羟基-4-吡喃酮原子被1至6个碳原子的脂族烃基取代; 或（2）通过1〜6个碳原子的脂族烃基，其中与氮原子连接的氢原子被脂肪族酰基取代的3-羟基吡啶-2-酮或3-羟基吡啶-4-酮，或通过被一个取代的脂肪族烃基，或者除了可离子化基团以外的多个选自脂肪族酰基，烷氧基，脂肪族胺，脂肪族酰胺，羧基，脂肪族酯，卤素，羟基和磺基的取代基的脂肪族烃基，其中一个或多个与环碳原子连接的氢原子被一个所述取代基取代，被1至6个碳原子的脂族烃基取代，或被被烷氧基，脂族酯，卤素取代的脂族烃基取代或羟基; 在药物中具有价值，特别是在锌耗竭的全身治疗中。这些锌配合物与提供其中所含配体的金属化合物和含有（1）和（2）类型配体的铁（III）配合物的混合物也是有价值的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式